Controlling Aedes mosquitoes in Kinshasa
Official title: Implementation and Evaluation of Vector Control Methods in Kinshasa: The Case of Aedes, Vectors of Arboviruses.
Run by Institute of Tropical Medicine, Belgium · NCT06981442 · Data updated 2026-11-12
This study is testing different ways to control Aedes mosquitoes in Kinshasa to see if it helps reduce the spread of diseases like dengue and chikungunya.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 2050 (estimated) |
| Sponsor | Institute of Tropical Medicine, Belgium Academic / other |
| Locations | 1 site (Kinshasa, République Démocratique Du Congo) |
| Status | Recruiting |
| Started | March 26, 2025 |
| Main results expected | September 30, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | August 19, 2026 |
| Trial ID | NCT06981442 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older who reside in selected health areas of Kinshasa and consent to participate.
✕Probably not a fit
Patients who are under 18 years of age, seriously ill, or not residing in the designated health zones may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to implement and evaluate various strategies for controlling Aedes mosquitoes, which are responsible for transmitting diseases like dengue and chikungunya, in Kinshasa, Democratic Republic of the Congo. It will utilize a before-and-after interventional approach to assess the effectiveness of community-based environmental management and targeted vector control methods at different life stages of the mosquitoes. Additionally, a serological survey will be conducted to gather data on the prevalence of Aedes-borne diseases in the area, enhancing understanding of their circulation.
Why it matters
Potential benefit: If successful, this study could significantly reduce the incidence of Aedes-borne diseases in the affected populations.
How similar studies have gone: Other studies have shown success with similar vector control approaches, indicating potential for effective interventions in this context.
Who can join: the full rules
Show full inclusion / exclusion criteria
At household level: Inclusion Criteria: * Belong to a household in one of the 4 health areas selected as study arms * From 18 years of age to consent for household enrollment and participation in the serosurvey * Consenting Exclusion Criteria: * Not belong to a household in one of the 4 health areas selected as study arms * Under 18 years of age * Non-consenting At health facility level: Inclusion Criteria: * From 18 years of age * Resident of the health zone of Mont Ngafula 1 * Consenting Exclusion Criteria: * Under 18 years of age * Not resident in the health zone of Mont Ngafula 1 * Seriously ill and hospitalized, requiring transfusion, presence of blood clotting disorders, allergies resulting from injections, adverse events associated with previous blood sampling, pregnancy * Non-consenting
Where it's running
-
Institut National de Recherche Biomédicale, INRB
Kinshasa, République Démocratique Du Congo, Democratic Republic of the Congo Recruiting
Study contacts
- Principal investigator: Veerle Vanlerberghe — Institute of Tropical Medicine Antwerp
- Study coordinator: Luciana Lepore
- Email: llepore@itg.be
- Phone: +32(0)32476666
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Eliminating Gambiense sleeping sickness using a single-dose oral treatment in screened seropositive people
This trial tests whether giving a single dose of acoziborole to people who test positive in screening for Gambiense human African trypanosomiasis can reduce disease transmission over three years.
-
Immunogenicity screening of Leishmania vaccine candidate antigens in Ethiopian patients
This study tests whether six Leishmania vaccine candidate antigens can trigger T-cell responses in patients with cutaneous or visceral leishmaniasis.
-
Baseline skin memory T cells in unvaccinated volunteers
This study tests the natural baseline levels of skin-resident memory T cells in healthy people who have not received the yellow fever vaccine.
-
Recurrent visceral leishmaniasis in people living with HIV
This project will follow adults living with HIV who develop visceral leishmaniasis to see if differences in the patient or the parasite explain why some people have repeated relapses.
-
Improving care and surveillance of fevers in the DRC
This project tracked people with recent fevers at two hospitals in the DRC to see what causes their fevers, how they are treated, and whether biomarkers like CRP relate to outcomes and antibiotic use.
-
Understanding the spread and impact of monkeypox in the Democratic Republic of Congo
This study is trying to understand how monkeypox spreads and affects people in the Democratic Republic of Congo by comparing those who have the virus to those who don’t.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.